Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Inaba, Hiroto , Teachey, David T. , Annesley, Colleen , Batra, Sandeep , Beck, Jill C., Cooper, Stacy , Dallas, Mari , Oliveira, Satiro De , Kelly, Kara M. , Kohorst, Mira A. , Kutny, Matthew A. , Lee‐Miller, Cathy , Ludwig, Kathleen , Madden, Lisa, Maloney, Kelly W. , Massaro, Stephanie, Morocco, Perry , Muller, Brad, Murphy, Lindsey , Nardi, Valentina , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Wong, Victor , Yanik, Gregory A. , Stehman, Katie, Inaba, Hiroto , Colace, Susan I. , Kitko, Carrie L. , Lacayo, Norman James , Mangum, David Spencer , McCall, David C. , Shah, Bijal , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 41-62

10.6004/jnccn.2025.0006 | PMID 39938467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.
Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET
Przybelski, Scott A. , Wiste, Heather J. , Fought, Angela J. , Jack, Clifford R. , Lowe, Val J. , Petersen, Ronald C. , Kantarci, Kejal , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Kantarci, Kejal , Mak, Elijah , Schwarz, Christopher G. , Senjem, Matthew L. , Boeve, Bradley F. , O'Brien, John Tiernan , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | February 12, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14571 | PMID 39935389 Get It

Abstract INTRODUCTION We investigated the association between alpha‐synuclein (α‐syn) pathology and brain glucose metabolism across the cognitive spectrum of Alzheimer's disease (AD) co‐pathologies. METHODS Fluorodeoxyglucose positron emission tomography (FDG‐PET) data from 829 Alzheimer's Disease Neuroimaging Initiative participants (648 cognitively impaired [CI], 181 unimpaired [CU]) were compared between α‐syn seed amplification assay (SAA) positive and negative groups. Interactions with cerebrospinal fluid (CSF) AD biomarkers were examined. RESULTS SAA+ was associated with widespread hypometabolism among CI individuals, particularly in posterior cortical regions, independent of CSF amyloid and tau levels in the occipital lobes. Regional hypometabolism mediated the effect of α‐syn SAA on disease severity in CI individuals, independent of CSF amyloid and tau levels. There were no influences of SAA on FDG‐PET in CU individuals. DISCUSSION This study supports a model in which α‐syn aggregation influences metabolic dysfunction, which then influences clinical disease severity, independent of AD. SAA+ could help optimize participant selection and outcome measures for clinical trials in AD. Highlights α‐synuclein seed amplification positivity (SAA+) was associated with hypometabolism in cognitively impaired individuals. Hypometabolism mediated the influence of α‐synuclein on disease severity. Occipital hypometabolism in SAA+ was independent of cerebrospinal fluid levels of Alzheimer's disease pathology. These findings can optimize future clinical trials targeting α‐synuclein pathology.
Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma
Wu, Grace , Standring, Oliver , King, Daniel A. , Gholami, Sepideh , Thiels, Cornelius A. , Grotz, Travis E. , Weiss, Matthew J. , Whelan, Richard L., Raoof, Mustafa , DePeralta, Danielle K. , Thiels, Cornelius A , Grotz, Travis E , DePeralta, Danielle K , Devoe, Craig

Mayo Clinic

Current Oncology | February 12, 2025 | Volume: 32 | Issue: 2 | Pages: 103

10.3390/curroncol32020103 | PMID 39996904 Get It

The peritoneum is the second most common site of metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Up to half of all patients that undergo curative-intent resection eventually develop peritoneal metastasis (PM), which accounts for significant morbidity and drives mortality. Despite recent advances in management, PM is associated with very poor prognosis, which is often measured in weeks to months. Clinical manifestations including bowel obstruction, ascites, and urinary obstruction have profound impact on quality of life. Even with relatively advanced disease, PM often remains occult on imaging and thus tend to be underdiagnosed and understudied. Many patients with peritoneal-only PM are excluded from clinical trials because response cannot be measured by standard radiographic criteria. Furthermore, as patients with PM are not eligible for surgical resection and low-volume peritoneal disease is often not amenable to percutaneous biopsy, tissue samples for peritoneal-specific translational studies are limited. Intraperitoneal therapeutics have been proposed as an attractive option for PM, as better penetration of tumor tissue can be achieved with less systemic toxicity compared with intravenous chemotherapy. Heated intraperitoneal chemotherapy (HIPEC), typically combined with cytoreductive surgery (CRS), is an option for select patients with PM from gynecologic or gastrointestinal primary, and for patients with primary peritoneal mesothelioma. However, the incorporation of locoregional therapy for PM in patients with PDAC has been poorly studied given the aggressive nature of pancreatic cancer and overall poor prognosis. With recent advances in existing treatment options, there may be a subset of patients who may derive benefits from locoregional control with cytoreduction and/or intraperitoneal chemotherapy. Critically, additional work is needed to determine PM-favorable clinical and tumoral predictive biomarkers to identify patients who may benefit from a more aggressive approach. We describe the current state of management of patients with peritoneal metastasis from PDAC and review the available data exploring peritoneal-directed therapy with cytoreductive surgery and/or intraperitoneal chemotherapy.
Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida
Rogina, Blanka , Anderson, Rozalyn M. , Curan, Sean, Yousefzadeh, Matthew J. , Ghosh, Bhaswati, Duque, Gustavo , Howlett, Susan E. , Austad, Steven N. , Korfhage, Justin , Christensen, Kaare , Carey, James R. , Bell, Justice, Gomes, Ana P. , Dixit, Vishwa Deep , Sen, Payel , Imai, Shin‐ichiro , Valdez, Gregorio , Orr, Miranda E. , Jones, Leanne , Castillo-Azofeida, David, Bonaguidi, Michael A. , Suh, Yousin , Duncan, Francesca E. , C, Weigler G Perry, Burkewitz, Kristopher , Zhou, Kai , Bouhrara, Mustapha , Kolind, Shannon , Dean, Doug, Pálovics, Róbert , Niedernhofer, Laura J. , Fan, Rong , Bueckle, Andreas , Kapahi, Pankaj , Jiang, Nisi , Diaz, Jose , Mishra, Sidharth P. , Ralmundo, Nuno, Banarjee, Reema , Allsopp, Richard , Curran, Sean P. , Anderson, Rozalyn M , Curran, Sean P , Yousefzadeh, Matthew J , Duque, Gustavo , Howlett, Susan , Austad, Steven , Demuth, Ilja , Gerstorf, Denis , Abadir, Peter , Christensen, Kaare , Palmer, Allyson, Basisty, Nathan , de Cabo, Rafael , Sen, Payel , Baur, Joseph A , Duncan, Francesca E , Benjamini, Dan , Walker, Keenan A , Dean, Douglas C , Gladyshev, Vadim N , Fan, Rong , Sato, Shogo , Jiang, Nisi , Ashiqueali, Sarah A., Allsopp, Richard , Niedernhofer, Laura J , Kollind, Shannon H , LeBrasseur, Nathan K. , Lombard, David B. , Alberts, Susan C. , Campos, Fernando A. , Palavicini, Juan Pablo , Palmer, Allyson K. , Basisty, Nathan , Cabo, Rafael de , Baur, Joseph A. , Li, Xiaoling , Pletcher, Scott D. , Andersen, Julie Kay , Jones, Leanne, Suh, Yousin , Murray, Anna , Wang, Meng C., Henne, W. Mike , Walker, Keenan A. , Reiter, David A. , Gorbunova, Vera , Gladyshev, Vadim N. , Hurley, Jennifer , Esser, Karyn A. , Ashiqueali, Sarah , Reynolds, Lindsay M. , Zhang, Bohan , Sebastiani, Paola , Monti, Stefano , Schork, Nicholas J. , Rappaport, Noa

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | February 11, 2025 | Volume: 80 | Issue: 5 | Pages: No page available

10.1093/gerona/glaf026 | PMID 39932386 Get It

Abstract The aging process is universal, and it is characterized by a progressive deterioration and decrease in physiological function leading to decline on the organismal level. Nevertheless, a number of genetic and nongenetic interventions have been described, which successfully extend healthspan and lifespan in different species. Furthermore, a number of clinical trials have been evaluating the feasibility of different interventions to promote human health. The goal of the annual Biological Sciences Section of the Gerontological Society of America meeting was to share current knowledge of different topics in aging research and provide a vision of the future of aging research. The meeting gathered international experts in diverse areas of aging research including basic biology, demography, and clinical and translational studies. Specific topics included metabolism, inflammaging, epigenetic clocks, frailty, senescence, neuroscience, stem cells, reproductive aging, inter-organelle crosstalk, comparative transcriptomics of longevity, circadian clock, metabolomics, and biodemography.
Access to Cochlear Implantation: Trends in Surgeon Volume and Training
Espahbodi, Mana , Trautwein, Patricia G., Bestourous, Daniel E. , Zwolan, Teresa A. , Nassiri, Ashley M. , Carlson, Matthew L. , Patel, Neil S. , Gurgel, Richard K. , Gurgel, Richard Klaus , Erbele, Isaac D.

Mayo Clinic

The Laryngoscope | February 11, 2025 | Volume: 135 | Issue: 6 | Pages: 2146-2153

10.1002/lary.32037 | PMID 39932075 Get It

Objectives Evaluate the training background of surgeons performing high volumes of cochlear implants (CIs) and estimate the ratio of providers trained in otology/neurotology (O&N) to the number of traditional CI candidates and audiologists. Methods A retrospective review of US surgeon registration data from a single CI manufacturer was performed to determine CI volume based on surgeon training. The prevalence of traditional candidates for CIs was estimated from US census population data and compared with the number of O&N providers. The ratio of audiologists to O&N providers was estimated from the Bureau of Labor and Statistics and American Speech‐Language‐Hearing Association databases. Results From 2021 to 2023, a mean of 88% of providers performing ≥25 CIs per year and 90% performing ≥40 per year had training in O&N. All surgeons registering ≥100 implants per year were O&N providers. The mean percentage of O&N providers performing ≥25 CIs per year and ≥ 40 per year was higher than the percentage of General and Pediatric Otolaryngology providers performing the same volume: mean difference = 76%, p < 0.001 and mean difference = 79%, p < 0.001, respectively. The mean estimated prevalence of traditional CI candidates per O&N provider is 3,354 with an estimated mean of 32 audiologists (3.5 trained in CIs) per O&N provider. Conclusion 88% of high‐volume CI surgeons have fellowship training in O&N. To meet the current state of CI underutilization and anticipated growing population of CI candidates, we propose increasing the surgical capacity of O&N providers and the number of surgeons proficient in CIs. Level of Evidence NA Laryngoscope , 135:2146–2153, 2025
Optimal Timing of Primary Radiosurgical Treatment of Growing Vestibular Schwannoma: Insights From Salvage Microsurgery Outcomes
Marinelli, John P. , Herberg, Hans A., Moore, Lindsay S. , Kay‐Rivest, Emily , Casale, Garrett G. , Durham, Allison, Khandalavala, Karl R. , Lund‐Johansen, Morten , Kosaraju, Nikitha , Lohse, Christine M. , Patel, Neil S. , Babu, Seilesh C. , Golfinos, John G. , Kutz, Joe Walter , Maria, Peter L. Santa , Link, Michael J., Tveiten, Øystein Vesterli , Carlson, Matthew L. , Yancey, Kristen L. , Gurgel, Richard Klaus , Roland, J. Thomas , Hunter, Jacob B. , Link, Michael J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 11, 2025 | Volume: 172 | Issue: 5 | Pages: 1717-1724

10.1002/ohn.1161 | PMID 39927827 Get It

AbstractObjectiveLimited evidence guides the optimal timing of treatment after the detection of tumor growth during the observation of sporadic vestibular schwannoma (VS). The current work aimed to inform the timing of radiosurgical intervention based on an analysis of patient outcomes among those who ultimately failed stereotactic radiosurgery (SRS) and underwent salvage microsurgery.Study DesignA historical cohort study.SettingSeven centers across the United States and Norway.MethodsAdults with sporadic VS who underwent salvage microsurgery following failed primary SRS were included. The primary outcome of interest was the association between tumor size at the time of primary SRS and the ability to achieve gross total resection (GTR) and maintain postoperative House–Brackmann (HB) facial nerve grade I at the last follow‐up after salvage microsurgery.ResultsAmong 96 patients, the median (interquartile range [IQR]) cerebellopontine angle (CPA) tumor size at primary SRS was 14.5 mm (10.0‐19.0). Each 1‐mm increase in CPA tumor size at the time of primary SRS was associated with a 13% increased likelihood of near‐total/subtotal resection or most recent postoperative HB grade >I (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.05‐1.21, P = .001), with an optimal tumor size threshold to distinguish this outcome of 12 mm of CPA extension (c‐index 0.73). Similarly, for each 1‐mm increase in CPA tumor size at the time of primary SRS, a 9% increase in any postoperative complication with salvage microsurgery was observed (OR 1.09, 95% CI 1.02‐1.15, P = .009).ConclusionCorroborated by size threshold surveillance data informing the timing of primary microsurgical resection, the current study suggests that VS outcomes are optimized when primary radiosurgical intervention is undertaken on growing tumors when they harbor 10–15 mm of cerebellopontine angle extension or less.
Rates and Predictors of Follow-Up Loss after Radiosurgery for Sporadic Vestibular Schwannomas
Alexander, A. Yohan , Nizzola, Mariagrazia , Amini, Misha, Pollock, Bruce E. , Carlson, Matthew L. , Driscoll, Colin L. W., Link, Michael , Morshed, Ramin A. , Alexander, A Yohan , Bauman, Megan M. J. , Brown, Paul

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803655 Get It

Differences in Disease Presentation and Rates of Positive Genetic Testing between Patients Diagnosed with NF2-Related Schwannomatosis Before and After 30 Years of Age
Carlson, Matthew L. , Neff, Brian, Driscoll, Colin L. W., Babovic‐Vuksanovic, Dusica , Dornhoffer, James R. , Olson, Brennan , Neff, Brian A., Schimmenti, Lisa A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803300 Get It

Enhancing Accuracy of Operative Reports with Automated Artificial Intelligence Analysis of Surgical Video
Khanna, Abhinav, Wolf, Tamir, Frank, Igor, Krueger, Alexander , Shah, Paras , Sharma, Vidit , Gettman, Matthew T., Boorjian, Stephen A. , Asselmann, Dotan, Tollefson, Matthew K.

Mayo Clinic

Journal of the American College of Surgeons | February 7, 2025 | Volume: 240 | Issue: 5 | Pages: 739-746

10.1097/xcs.0000000000001352 | PMID 39918224 Get It

BACKGROUND: The creation of operative reports is a tedious documentation task that increases administrative burden, which is a potential driver of burnout. Additionally, operative reports are inherently subjective and may contain inaccuracies and incomplete information. Recent advances in artificial intelligence (AI) technology have enabled computer vision systems to accurately detect operative steps on surgical video. We aim to develop a platform for the automated creation of video-based AI surgical operative reports in robotic-assisted radical prostatectomy. STUDY DESIGN: An AI computer vision algorithm was used to automatically detect surgical steps. Each step detected on video was mapped to prespecified text, which was then compiled into a narrative AI operative report. The accuracy of the AI operative reports was compared with operative reports written by surgeons, using expert review of raw surgical video footage as the ground truth. RESULTS: A total of 158 cases from a tertiary referral center were included. In surgeon operative reports, 84 cases (53.2%) had at least 1 discrepancy between the operative report and surgical video. Of these, 43 cases (27.2%) had a clinically significant discrepancy based on expert video review. In AI operative reports, 46 cases (29.1%) had at least 1 discrepancy between the operative report and surgical video. Of these, 20 cases (12.7%) had a clinically significant discrepancy. Overall accuracy was higher for AI operative reports compared with surgeon operative reports (87.3% vs 72.8%, p = 0.001). CONCLUSIONS: Operative reports created by AI achieved higher accuracy than those written by surgeons. To our knowledge, this is the first report of automated video-based AI surgical documentation. Future studies are warranted to explore the potential for this novel tool to reduce documentation burden, improve operative report accuracy, promote surgical transparency, and decrease subjectivity in surgical documentation.